Advertisement

Infection

, Volume 46, Issue 4, pp 549–554 | Cite as

Early treatment of tuberculous uveitis improves visual outcome: a 10-year cohort study

  • Luis Anibarro
  • Eliana Cortés
  • Ana Chouza
  • Alberto Parafita-Fernández
  • Juan Carlos García
  • Alberto Pena
  • Carlos Fernández-Cid
  • África González-Fernández
Original Paper
  • 112 Downloads

Abstract

Purpose

Diagnosis of tuberculous uveitis (TBU) is often challenging and is usually made after excluding other causes of uveitis. We analysed the characteristics of TBU and variables associated with visual outcome.

Methods

A retrospective, observational analysis was performed in patients with presumptive TBU who were started on specific TB treatment between January 2006 and June 2016. Demographic, clinical, radiological, analytical and ophthalmic examination variables were studied. After completing TB treatment, a follow-up of at least 9 months was performed. A univariate and logistic regression analysis was applied to identify the variables associated with visual acuity and recurrences of uveitis.

Results

Forty affected eyes of 24 individuals were identified; 79% of patients were diagnosed during the last 3 years of the study period. Median delay from onset of symptoms to diagnosis was 12 weeks. Loss of visual acuity was the most frequent symptom (87.5%). Posterior uveitis was the most frequent localization (72.9%); 19 patients (79.2%) presented at least one of the Gupta signs predictive of TBU, but there were no confirmed diagnoses.

Outcome

There was improvement in visual acuity in 74.4% of the eyes, but a complete response was achieved only in 56.4%. There was recurrence in two patients. The initiation of treatment ≥ 24 weeks after onset of symptoms was significantly associated with no improvement (p = 0.026).

Conclusion

TBU can cause permanent damage to visual acuity, particularly in patients with delayed diagnosis. A prompt initiation of systemic TB treatment is essential to improve visual prognosis.

Keywords

Tuberculosis Uveitis Intraocular tuberculosis 

Notes

Acknowledgements

Fundación Galicia Sur Statistics Foundation for statistical support.

Funding

Without financing.

Compliance with ethical standards

An institucional Review Board approval was obtained from the Comité Ético de Investigación Galicia Sur (registration code 2017/007.

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

References

  1. 1.
    Cordero-Coma M, Salazar R, Costales F. Tuberculous uveitis: an update. Expert Rev Ophthalmol. 2014;9:125–37.  https://doi.org/10.1586/17469899.2014.897228.CrossRefGoogle Scholar
  2. 2.
    Lee C, Agrawal R, Pavesio C. Ocular tuberculosis. A clinical conundrum. Ocul Immunol Inflamm. 2016;24:237–42.  https://doi.org/10.3109/09273948.2014.985387.CrossRefPubMedGoogle Scholar
  3. 3.
    Lou SM, Larkin KL, Winthrop K, Rosenbaum JT, Group USS. Lack of consensus in the diagnosis and treatment for ocular tuberculosis among uveitis specialists. Ocul Immunol Inflamm. 2015;23:25–31.  https://doi.org/10.3109/09273948.2014.926936.CrossRefPubMedGoogle Scholar
  4. 4.
    Alvarez GG, Roth VR, Hodge W. Ocular tuberculosis: diagnostic and treatment challenges. Int J Infect Dis. 2009;13:432–5.  https://doi.org/10.1016/j.ijid.2008.09.018.CrossRefPubMedGoogle Scholar
  5. 5.
    Ang M, Chee SP. Controversies in ocular tuberculosis. Br J Ophthalmol. 2017;101:6–9.  https://doi.org/10.1136/bjophthalmol-2016-309531.CrossRefPubMedGoogle Scholar
  6. 6.
    Levenson JH, Kozarsky K. Visual Acuity. In: Walker HK, Hall WD, Hurst JW, editors. Clinical methods: the history, physical, and laboratory examinations. 3rd ed. Boston: Butterworths; 1990, pp. 563–4.Google Scholar
  7. 7.
    Jabs DA, Nussenblatt RB, Rosenbaum JT, Group SoUNSW. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–16.CrossRefPubMedGoogle Scholar
  8. 8.
    Gupta A, Sharma A, Bansal R, Sharma K. Classification of intraocular tuberculosis. Ocul Immunol Inflamm. 2015;23:7–13.  https://doi.org/10.3109/09273948.2014.967358.CrossRefPubMedGoogle Scholar
  9. 9.
    Ang L, Kee A, Yeo TH, Dinesh VG, Ho SL, Teoh SC, et al. Treatment outcome in patients with presumed tubercular uveitis at a tertiary referral eye care centre in Singapore. Int Ophthalmol. 2016.  https://doi.org/10.1007/s10792-016-0401-6.PubMedGoogle Scholar
  10. 10.
    Gupta A, Bansal R, Gupta V, Sharma A, Bambery P. Ocular signs predictive of tubercular uveitis. Am J Ophthalmol. 2010;149:562–70.  https://doi.org/10.1016/j.ajo.2009.11.020.CrossRefPubMedGoogle Scholar
  11. 11.
    Agrawal R, Gupta B, Gonzalez-Lopez JJ, Rahman F, Phatak S, Triantafyllopoulou I, et al. The role of anti-tubercular therapy in patients with presumed ocular tuberculosis. Ocul Immunol Inflamm. 2015;23:40–6.  https://doi.org/10.3109/09273948.2014.986584.CrossRefPubMedGoogle Scholar
  12. 12.
    Bajema KL, Pakzad-Vaezi K, Hawn T, Pepple KL. Tuberculous uveitis: association between anti-tuberculous therapy and clinical response in a non-endemic country. J Ophthalmic Inflamm Infect. 2017;7:19.  https://doi.org/10.1186/s12348-017-0137-0.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Mora P, Ghirardini S, Héron E, Sedira N, Olcelli F, Gandolfi S, et al. Ocular tuberculosis: experience of an Italian and French cohort. Acta Ophthalmol. 2015;93:e403-4.  https://doi.org/10.1111/aos.12602.CrossRefPubMedGoogle Scholar
  14. 14.
    Agrawal R, Gunasekeran DV, Grant R, Agarwal A, Kon OM, Nguyen QD, et al. Clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the collaborative ocular tuberculosis study (COTS)-1. JAMA Ophthalmol. 2017;135:1318–27.  https://doi.org/10.1001/jamaophthalmol.2017.4485.CrossRefPubMedGoogle Scholar
  15. 15.
    Kee AR, Gonzalez-Lopez JJ, Al-Hity A, Gupta B, Lee CS, Gunasekeran DV, et al. Anti-tubercular therapy for intraocular tuberculosis: a systematic review and meta-analysis. Surv Ophthalmol. 2016;61:628–53.  https://doi.org/10.1016/j.survophthal.2016.03.001.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Smit DP, Esterhuizen TM, Meyer D. The prevalence of intraocular tuberculosis in HIV-positive and HIV-negative patients in south africa using a revised classification system. Ocul Immunol Inflamm. 2016;23:1–8.  https://doi.org/10.1080/09273948.2016.1263342.Google Scholar
  17. 17.
    Tognon MS, Fiscon M, Mirabelli P, Graziani G, Peracchi M, Sattin A, et al. Tuberculosis of the eye in Italy: a forgotten extrapulmonary localization. Infection. 2014;42:335–42.  https://doi.org/10.1007/s15010-013-0554-4.CrossRefPubMedGoogle Scholar
  18. 18.
    Cordero-Coma M, Garzo I, Salazar R, Franco M, Calleja S, Ruiz de Morales JM. Treatment of presumed tuberculous uveitis affecting the posterior segment: diagnostic confirmation and long term outcomes. Arch Soc Esp Oftalmol. 2013;88:339–44.  https://doi.org/10.1016/j.oftal.2012.11.011.CrossRefPubMedGoogle Scholar
  19. 19.
    Li KK, Chan WM, Tam BS, Ng JS, Lam DS. Needle tap in the diagnosis of inflammation. Ophthalmology. 2004;111:609.  https://doi.org/10.1016/j.ophtha.2003.12.036 (author reply—10).CrossRefPubMedGoogle Scholar
  20. 20.
    Sharma K, Gupta V, Bansal R, Sharma A, Sharma M, Gupta A. Novel multi-targeted polymerase chain reaction for diagnosis of presumed tubercular uveitis. J Ophthalmic Inflamm Infect. 2013;3:25.  https://doi.org/10.1186/1869-5760-3-25.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Bouza E, Merino P, Muñoz P, Sanchez-Carrillo C, Yáñez J, Cortés C. Ocular tuberculosis. A prospective study in a general hospital. Medicine (Baltimore). 1997;76:53–61.CrossRefGoogle Scholar
  22. 22.
    Troutbeck R, Lim LL. Clinical controversy: to treat, or not to treat? That is the tuberculosis question. Clin Exp Ophthalmol. 2012;40:653–4.  https://doi.org/10.1111/j.1442-9071.2012.02855.x.CrossRefPubMedGoogle Scholar
  23. 23.
    Abrams J, Schlaegel TF. The role of the isoniazid therapeutic test in tuberculous uveitis. Am J Ophthalmol. 1982;94:511–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Bansal R, Gupta A, Gupta V, Dogra MR, Bambery P, Arora SK. Role of anti-tubercular therapy in uveitis with latent/manifest tuberculosis. Am J Ophthalmol. 2008;146:772–9.  https://doi.org/10.1016/j.ajo.2008.06.011.CrossRefPubMedGoogle Scholar
  25. 25.
    Patel SS, Saraiya NV, Tessler HH, Goldstein DA. Mycobacterial ocular inflammation: delay in diagnosis and other factors impacting morbidity. JAMA Ophthalmol. 2013;131:752–8.  https://doi.org/10.1001/jamaophthalmol.2013.71.CrossRefPubMedGoogle Scholar
  26. 26.
    González-Martín J, García-García J, Anibarro L, Vidal R, Esteban J, Blanquer R, et al. Consensus document on the diagnosis, treatment and prevention of tuberculosis. Enferm Infecc Microbiol Clin. 2010;28:297.e1-20.  https://doi.org/10.1016/j.eimc.2010.02.006.CrossRefPubMedGoogle Scholar
  27. 27.
    Ang M, Hedayatfar A, Wong W, Chee SP. Duration of anti-tubercular therapy in uveitis associated with latent tuberculosis: a case–control study. Br J Ophthalmol. 2012;96:332–6.  https://doi.org/10.1136/bjophthalmol-2011-300209.CrossRefPubMedGoogle Scholar
  28. 28.
    Ng KK, Nisbet M, Damato EM, Sims JL. Presumed tuberculous uveitis in non-endemic country for tuberculosis: case series from a New Zealand tertiary uveitis clinic. Clin Exp Ophthalmol. 2017;45:357–65.  https://doi.org/10.1111/ceo.12881.CrossRefPubMedGoogle Scholar
  29. 29.
    Krassas N, Wells J, Bell C, Woodhead M, Jones N. Presumed tuberculosis-associated uveitis: rising incidence and widening criteria for diagnosis in a non-endemic area. Eye (Lond). 2018;32:87–92.  https://doi.org/10.1038/eye.2017.152.CrossRefGoogle Scholar
  30. 30.
    La Distia Nora R, van Velthoven ME, Ten Dam-van Loon NH, Misotten T, Bakker M, van Hagen MP, et al. Clinical manifestations of patients with intraocular inflammation and positive QuantiFERON-TB gold in-tube test in a country nonendemic for tuberculosis. Am J Ophthalmol. 2014;157:754 – 61.  https://doi.org/10.1016/j.ajo.2013.11.013.CrossRefPubMedGoogle Scholar
  31. 31.
    Trad S, Bodaghi B, Saadoun D. Update on immunological test (Quantiferon-TB Gold) contribution in the management of tuberculosis-related ocular inflammation. Ocul Immunol Inflamm. 2017.  https://doi.org/10.1080/09273948.2017.1332232.Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Unidad de Tuberculosis, Enfermedades Infecciosas, Servicio de Medicina Interna, Complexo hospitalario universitario de PontevedraInstituto de Investigación Sanitaria Galicia SurPontevedraSpain
  2. 2.Inmunología, Centro de investigaciones Biomédicas, CINBIO, Centro Singular de Investigación de GaliciaUniversidad de VigoVigoSpain
  3. 3.Servicio de Medicina InternaHospital universitario Ramón y CajalMadridSpain
  4. 4.Servicio de OftalmologíaComplexo hospitalario universitario de PontevedraPontevedraSpain

Personalised recommendations